PUMA BIOTECHNOLOGY, INC. - 10-Q Filing
Puma Biotechnology reports Q3 2026 financial results with $51.7M in total assets and significant R&D expense components.
Tickers: $PBYI
Read the full article at SEC EDGAR
Part of the story Sana Biotechnology, Inc. - 10-Q Filing (3 articles)